Defibrotide improves COVID-19-related acute respiratory distress syndrome in myeloma patients after chimeric antigen receptor T-cell treatment without compromising virus-specific and anti-myeloma T-cell responses
Mehmet H. Kocoglu,
Paul G. Richardson,
Clifton C. Mo,
Aaron P. Rapoport,
Djordje Atanackovic
Affiliations
Mehmet H. Kocoglu
University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; Transplant and Cellular Therapy Program, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
Paul G. Richardson
Dana Farber Cancer Institute, Boston, MA
Clifton C. Mo
Dana Farber Cancer Institute, Boston, MA
Aaron P. Rapoport
University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; Transplant and Cellular Therapy Program, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
Djordje Atanackovic
University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; Transplant and Cellular Therapy Program, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; Department of Microbiology and Immunology, University of Maryland, Baltimore, MD
